Esther Rajavelu

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) reported fourth-quarter sales and revenues that slightly exceeded estimates but issued a guarded outlook for 2020. The Teva Analysts BofA Securities analyst Jason Gerberry reiterated an Underperform rating on Teva and raised the price target from $8...